Cargando…

Development of a Prototype, Once-Daily, Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772

PURPOSE: GSK2982772 is a selective inhibitor of receptor-interacting protein kinase-1, with a 2–3 h half-life. This study evaluated if a once-daily modified-release formulation of GSK2982772 could be developed with no significant food effect. METHODS: Part A evaluated the pharmacokinetics of GSK2982...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tompson, Debra J., Whitaker, Mark, Pan, Rennan, Johnson, Geoffrey, Fuller, Teresa, McKenzie, Litza, Zann, Vanessa, Powell, Marcy, Abbott-Banner, Kathy, Hawkins, Simon
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2021
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8292240/ https://www.ncbi.nlm.nih.gov/pubmed/34136987 http://dx.doi.org/10.1007/s11095-021-03059-z

Ejemplares similares

Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology
por: Tompson, Debra, et al.
Publicado: (2022)

A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis
por: Weisel, Kathy, et al.
Publicado: (2021)

Comparison of the Pharmacokinetics of RIPK1 Inhibitor GSK2982772 in Healthy Western and Japanese Subjects
por: Tompson, Debra J., et al.
Publicado: (2020)

Randomized clinical study of safety, pharmacokinetics, and pharmacodynamics of RIPK1 inhibitor GSK2982772 in healthy volunteers
por: Weisel, Kathleen, et al.
Publicado: (2017)

A randomized, placebo-controlled experimental medicine study of RIPK1 inhibitor GSK2982772 in patients with moderate to severe rheumatoid arthritis
por: Weisel, Kathleen, et al.
Publicado: (2021)

Phase I evaluation of the safety, tolerability, and pharmacokinetics of GSK3640254, a next‐generation HIV‐1 maturation inhibitor
por: Joshi, Samit R., et al.
Publicado: (2020)

Experiments and Cycling at the LHC Prototype Half-Cell
por: Saban, R, et al.
Publicado: (1998)

Glass half empty? Lessons learned about gastroparesis
por: McKenzie, Patrick, et al.
Publicado: (2018)

Response to Inhibition of Receptor‐Interacting Protein Kinase 1 (RIPK1) in Active Plaque Psoriasis: A Randomized Placebo‐Controlled Study
por: Weisel, Kathleen, et al.
Publicado: (2020)

One half of a prototype titanium vacuum chamber
por: CERN PhotoLab
Publicado: (1973)

The Role of RIPK1 and RIPK3 in Cardiovascular Disease
por: DeRoo, Elise, et al.
Publicado: (2020)

Half Dose Once-Daily Pemafibrate Effectively Improved Hypertriglyceridemia in Real Practice
por: Iitake, Chie, et al.
Publicado: (2019)

Lesion remyelinating activity of GSK239512 versus placebo in patients with relapsing-remitting multiple sclerosis: a randomised, single-blind, phase II study
por: Schwartzbach, Caryl J., et al.
Publicado: (2016)

Ripk1 and haematopoiesis: a case for LUBAC and Ripk3
por: Annibaldi, Alessandro, et al.
Publicado: (2018)

Mechanical and Thermal Characterisation of a TT Half-Module Prototype
por: Lehner, F, et al.
Publicado: (2005)

GSK840 Alleviates Retinal Neuronal Injury by Inhibiting RIPK3/MLKL-Mediated RGC Necroptosis After Ischemia/Reperfusion
por: Feng, Yanlin, et al.
Publicado: (2023)

RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury
por: Newton, K, et al.
Publicado: (2016)

RIPK1 blocks T cell senescence mediated by RIPK3 and caspase-8
por: Imanishi, Takayuki, et al.
Publicado: (2023)

TNF can activate RIPK3 and cause programmed necrosis in the absence of RIPK1
por: Moujalled, D M, et al.
Publicado: (2013)

HIV-1 protease cleaves the serine-threonine kinases RIPK1 and RIPK2
por: Wagner, Roland N., et al.
Publicado: (2015)

Identification of MYC as an antinecroptotic protein that stifles RIPK1–RIPK3 complex formation
por: Seong, Daehyeon, et al.
Publicado: (2020)

TRAF6 regulates the abundance of RIPK1 and inhibits the RIPK1/RIPK3/MLKL necroptosis signaling pathway and affects the progression of colorectal cancer
por: Lin, Penghang, et al.
Publicado: (2023)

Necroptosis: Fifty shades of RIPKs
por: Ichim, Gabriel, et al.
Publicado: (2014)

RIPK1–RIPK3–MLKL-Associated Necroptosis Drives Leishmania infantum Killing in Neutrophils
por: Barbosa, Laiana A., et al.
Publicado: (2018)

TRADD regulates perinatal development and adulthood survival in mice lacking RIPK1 and RIPK3
por: Dowling, John P., et al.
Publicado: (2019)

Ubiquitylation of RIPK3 beyond-the-RHIM can limit RIPK3 activity and cell death
por: Frank, Daniel, et al.
Publicado: (2022)

RIPK1 and RIPK3 inhibitors: potential weapons against inflammation to treat diabetic complications
por: Ke, Dan, et al.
Publicado: (2023)

RIPK1-RIPK3-MLKL-dependent necrosis promotes the aging of mouse male reproductive system
por: Li, Dianrong, et al.
Publicado: (2017)

Mutations that prevent caspase cleavage of RIPK1 cause autoinflammatory disease
por: Lalaoui, Najoua, et al.
Publicado: (2019)

Execution of RIPK3-regulated necrosis
por: Cai, Zhenyu, et al.
Publicado: (2014)

Advances in RIPK1 kinase inhibitors
por: Chen, Lu, et al.
Publicado: (2022)

Differential roles of RIPK1 and RIPK3 in TNF-induced necroptosis and chemotherapeutic agent-induced cell death
por: Moriwaki, K, et al.
Publicado: (2015)

Ubiquitination of RIPK1 suppresses programmed cell death by regulating RIPK1 kinase activation during embryogenesis
por: Zhang, Xixi, et al.
Publicado: (2019)

Catecholamine Surges Cause Cardiomyocyte Necroptosis via a RIPK1–RIPK3-Dependent Pathway in Mice
por: Wu, Penglong, et al.
Publicado: (2021)

Investigation on the expression regulation of RIPK1/RIPK3 in the retinal ganglion cells (RGCs) cultured in high glucose
por: Gao, Sheng, et al.
Publicado: (2021)

RIPK1 and RIPK3 regulate TNFα-induced β-cell death in concert with caspase activity
por: Contreras, Christopher J., et al.
Publicado: (2022)

Human ZBP1 induces cell death‐independent inflammatory signaling via RIPK3 and RIPK1
por: Peng, Ruoshi, et al.
Publicado: (2022)

Inhibition of RIPK1 kinase does not affect diabetes development: β-Cells survive RIPK1 activation
por: Takiishi, Tatiana, et al.
Publicado: (2023)

Results on space measurement accuracy from tests of a half-scale DELPHI TPC prototype
por: Brand, C, et al.
Publicado: (1986)

Lysosomal damage after spinal cord injury causes accumulation of RIPK1 and RIPK3 proteins and potentiation of necroptosis
por: Liu, Shuo, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_54tebcb6hvrj6ra2n361m0qfhd